Archive

HIGHLIGHTS

 
LSP leads € 15M series A round of Cardiovascular start-up Cardior Pharmaceuticals
Munich, Germany — May 11, 2017 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series A Round of Cardior Pharmaceuticals, a private German company develo[...]
 
LSP Portfolio Company Luxendo acquired by Bruker
Successful exit after 1,5 years validates LSPs investment rationale   Munich, Germany ─ May 8, 2017 ─ LSP today announced that it has sold its portfolio company Luxendo, a spin-off of the European Molecul[...]
 
LSP extends its portfolio in immuno-oncology and invests in the € 20 million Series A round of Imcheck Therapeutics
Amsterdam, the Netherlands — May 3, 2017 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series A Round of Imcheck Therapeutics, a private French company[...]
 
Marco Groot blikt in het FD terug op zijn eerdere positieve aanbeveling op LSP
Lees de gehele column: Actief beleggen loont
 
LSP’s portfolio company Neuravi acquired by Codman Neuro
Amsterdam, the Netherlands, April 10, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces the acquisition of its portfolio company Neuravi Limited by Codman Neuro, part of the [...]
 
LSP’s portfolio company argenx raises approximately $100 million with NASDAQ IPO
Amsterdam, The Netherlands – 19 May 2017 – It is with great pleasure that LSP – the specialist European healthcare investment firm – announces that its portfolio company argenx (Euronext Brussels: ARGX) was su[...]
 
LSP announces $280 million final closing of life sciences venture fund
Amsterdam, 2nd June 2016 - LSP (Life Sciences Partners), the European life sciences investment group, today announced the final closing of its new life sciences fund, LSP 5. The fund surpassed its $170 million target [...]
 
LSP and Bristol-Myers Squibb enter into strategic collaboration for life sciences innovation in Europe
First investment by Bristol-Myers Squibb in a European healthcare fund      Munich and New York, 24 November, 2015—LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced to[...]
 
LSP Venture Partner Hans Clevers gets prestigious Körber Award for his ground breaking research into stem cells and organoids, and appears in Germ...
To see the video click here    
 
Wireless brain-spine connection to overcome paralysis
Prof Grégoire Courtine and Dr. Jocelyne Bloch, both founders of LSP’s portfolio company G-Therapeutics, have published in Nature that a wireless brain implant – that stimulates electrodes in the leg by recreating[...]
 
LSP COMPANY NEWS
LSP’s portfolio company Merus announces deal with Incyte
 
Marco Groot over LSP in het FD
Lees de gehele column: Een absoluut beter resultaat

2017


U.S. Court of Appeals for the Federal Circuit affairms Merus’ inequitable conduct claim against Regeneron
UTRECHT, The Netherlands, July 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that [...]
Kiadis Pharma proposes former Actelion COO Otto Schwarz as new Supervisory Board member
Amsterdam-Duivendrecht, The Netherlands, July 26, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing in [...]
LSP extends its portfolio in medical devices and invests in Simplify Medical
Amsterdam, the Netherlands - 20 July 2017 - LSP (Life Sciences Partners) announces its investment in Simplify Medical. Simplify Medical is focused on cervical spinal disc arthroplasty, using innovative, MRI-friendly m [...]
Merus Announces First Quarter 2017 Financial Results and Mid-Year Operating Results
Balance sheet strengthened with $120 million upfront payment and an $80 million share purchase from Incyte Corporation for global strategic research collaboration to discover and develop bispecific antibodies   [...]
Marco Groot blikt in het FD terug op zijn eerdere positieve aanbeveling op LSP
Lees de gehele column: Actief beleggen loont [...]
argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein at Best of ASCO Asia 2017 (Singapo...
Breda, the Netherlands / Ghent, Belgium, July 7, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]


2017
2016
2015
2014
2013
2012
back to news overview

Archive

HIGHLIGHTS

 
LSP leads € 15M series A round of Cardiovascular start-up Cardior Pharmaceuticals
Munich, Germany — May 11, 2017 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series A Round of Cardior Pharmaceuticals, a private German company develo[...]
 
LSP Portfolio Company Luxendo acquired by Bruker
Successful exit after 1,5 years validates LSPs investment rationale   Munich, Germany ─ May 8, 2017 ─ LSP today announced that it has sold its portfolio company Luxendo, a spin-off of the European Molecul[...]
 
LSP extends its portfolio in immuno-oncology and invests in the € 20 million Series A round of Imcheck Therapeutics
Amsterdam, the Netherlands — May 3, 2017 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series A Round of Imcheck Therapeutics, a private French company[...]
 
Marco Groot blikt in het FD terug op zijn eerdere positieve aanbeveling op LSP
Lees de gehele column: Actief beleggen loont
 
LSP’s portfolio company Neuravi acquired by Codman Neuro
Amsterdam, the Netherlands, April 10, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces the acquisition of its portfolio company Neuravi Limited by Codman Neuro, part of the [...]
 
LSP’s portfolio company argenx raises approximately $100 million with NASDAQ IPO
Amsterdam, The Netherlands – 19 May 2017 – It is with great pleasure that LSP – the specialist European healthcare investment firm – announces that its portfolio company argenx (Euronext Brussels: ARGX) was su[...]
 
LSP announces $280 million final closing of life sciences venture fund
Amsterdam, 2nd June 2016 - LSP (Life Sciences Partners), the European life sciences investment group, today announced the final closing of its new life sciences fund, LSP 5. The fund surpassed its $170 million target [...]
 
LSP and Bristol-Myers Squibb enter into strategic collaboration for life sciences innovation in Europe
First investment by Bristol-Myers Squibb in a European healthcare fund      Munich and New York, 24 November, 2015—LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced to[...]
 
LSP Venture Partner Hans Clevers gets prestigious “Körber Award” for his ground breaking research into stem cells and organoids, and appears in Germ...
To see the video click here    
 
Wireless brain-spine connection to overcome paralysis
Prof Grégoire Courtine and Dr. Jocelyne Bloch, both founders of LSP’s portfolio company G-Therapeutics, have published in Nature that a wireless brain implant – that stimulates electrodes in the leg by recreating[...]
 
LSP COMPANY NEWS
LSP’s portfolio company Merus announces deal with Incyte
 
Marco Groot over LSP in het FD
Lees de gehele column: Een absoluut beter resultaat

$smarty.now|date_format:"%Y"


U.S. Court of Appeals for the Federal Circuit affairms Merus’ inequitable conduct claim against Regeneron
UTRECHT, The Netherlands, July 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that [...]
Kiadis Pharma proposes former Actelion COO Otto Schwarz as new Supervisory Board member
Amsterdam-Duivendrecht, The Netherlands, July 26, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing in [...]
LSP extends its portfolio in medical devices and invests in Simplify Medical
Amsterdam, the Netherlands - 20 July 2017 - LSP (Life Sciences Partners) announces its investment in Simplify Medical. Simplify Medical is focused on cervical spinal disc arthroplasty, using innovative, MRI-friendly m [...]
Merus Announces First Quarter 2017 Financial Results and Mid-Year Operating Results
Balance sheet strengthened with $120 million upfront payment and an $80 million share purchase from Incyte Corporation for global strategic research collaboration to discover and develop bispecific antibodies   [...]
Marco Groot blikt in het FD terug op zijn eerdere positieve aanbeveling op LSP
Lees de gehele column: Actief beleggen loont [...]
argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein at Best of ASCO Asia 2017 (Singa...
Breda, the Netherlands / Ghent, Belgium, July 7, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]


2017
2016
2015
2014
2013
2012
back to news overview